SMS Pharmaceuticals (SMSPHARMA) Fundamentals 2026 — P/E 34.1x, Revenue Analysis | SniperIQ
SMS Pharmaceuticals (SMSPHARMA) is a India-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₹3,620 Crore, trading at ₹386.55 on the NSE. This SniperIQ fundamentals page covers SMS Pharmaceuticals's valuation (P/E 34.1x, P/B 4.5x), profitability (net margin 11.5%), revenue (₹887 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is SMS Pharmaceuticals's market cap?
SMS Pharmaceuticals (SMSPHARMA) has a market capitalization of approximately ₹3,620 Crore, trading at ₹386.55 on the NSE. Market cap moves with the live share price.
What is SMS Pharmaceuticals's P/E ratio?
SMS Pharmaceuticals's trailing twelve-month P/E ratio is 34.1x, with a price-to-book (P/B) of 4.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is SMS Pharmaceuticals?
SMS Pharmaceuticals runs a net profit margin of 11.5%, a gross margin of 25.7%, and an operating margin of 14.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does SMS Pharmaceuticals generate?
SMS Pharmaceuticals reported revenue of ₹887 Crore for fiscal year 2026, with net income of ₹102 Crore and earnings per share (EPS) of 11.15. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does SMS Pharmaceuticals pay a dividend?
SMS Pharmaceuticals offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is SMS Pharmaceuticals financially healthy?
SMS Pharmaceuticals carries a debt-to-equity ratio of 0.46x and a current ratio of 1.81x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is SMS Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SMS Pharmaceuticals (SMSPHARMA) the key facts are: market cap ₹3,620 Crore, P/E 34.1x, revenue ₹887 Crore, 52-week range 207.99-447.8. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track SMS Pharmaceuticals's full fundamentals live
Get SMS Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.